Company Coverage
Edge Medical (2675 HK): Price War Clouds 2026 Revenue; Seeking Strategic Shift Toward High-end Market Via New Product Launches
BUY (Maintained)
Current price:
Target price:
Upside:
Previous TP :
HK$27.88
HK$37.00
32.7%
HK$56.00
Analyst
Analyst
Highlights
- Our industry check has shown that fierce price competition in the surgical robot segment may lead to slower-than-expected revenue growth and depress profit margins for Edge Medical in 2026.
- Edge Medical expects to launch new products in 2027 competing directly with Intuitive Surgical’s most advanced model – da Vinci 5. The move will also allow the company to price the new products at favourable prices and promote a strategic shift towards high-end market share.
- Maintain BUY with a lower target price of HK$37.00 to reflect short-term price pressure.
Analysis
- Intensifying competition depresses product price. Our channel check indicates there is significant price competition among domestic surgical robotic players in both China and overseas. Edge Medical’s domestic product prices have lowered to Rmb7.5m-Rmb10m per unit compared with approximately Rmb12m-Rmb13m in 2025. Facing price competition from peers, the company has also lowered its price by 15-16% overseas in an effort to attract customers and expand market presence.
- Overseas sales volume remains strong. With continued globalisation effort, Edge Medical has continued to see robust volume growth in the international markets, eg in the EU, Southeast Aisa and other emerging markets. We are confident that the company will achieve its targeted total sales volume of 120-130 units in 2026, up approximately 70% from 2025. This supports strong momentum in overseas revenue in 2H26.
- Launching advanced products to capture high-end market share and support robust revenue and earnings expansion in 2027 and beyond. Amid intensifying competition, Edge Medical has further enhanced its brand strategy by localising operations, enhancing services, and through continued technological advancement to sustain rapid growth in the global market. It expects to launch new high-end surgical robot model in 2027. With enhanced visualisation and ergonomics, massive computing power, and greater surgeon autonomy, the new products will position the company at the forefront of the domestic players, competing directly with Intuitive Surgical’s most advanced model – da Vinci 5. The move will also allow the company to price these new products at favourable prices and promote a strategic shift towards high-end market share.
Highlights
- Our industry check has shown that fierce price competition in the surgical robot segment may lead to slower-than-expected revenue growth and depress profit margins for Edge Medical in 2026.
- Edge Medical expects to launch new products in 2027 competing directly with Intuitive Surgical’s most advanced model – da Vinci 5. The move will also allow the company to price the new products at favourable prices and promote a strategic shift towards high-end market share.
- Maintain BUY with a lower target price of HK$37.00 to reflect short-term price pressure.
Analysis
- Intensifying competition depresses product price. Our channel check indicates there is significant price competition among domestic surgical robotic players in both China and overseas. Edge Medical’s domestic product prices have lowered to Rmb7.5m-Rmb10m per unit compared with approximately Rmb12m-Rmb13m in 2025. Facing price competition from peers, the company has also lowered its price by 15-16% overseas in an effort to attract customers and expand market presence.
- Overseas sales volume remains strong. With continued globalisation effort, Edge Medical has continued to see robust volume growth in the international markets, eg in the EU, Southeast Aisa and other emerging markets. We are confident that the company will achieve its targeted total sales volume of 120-130 units in 2026, up approximately 70% from 2025. This supports strong momentum in overseas revenue in 2H26.
- Launching advanced products to capture high-end market share and support robust revenue and earnings expansion in 2027 and beyond. Amid intensifying competition, Edge Medical has further enhanced its brand strategy by localising operations, enhancing services, and through continued technological advancement to sustain rapid growth in the global market. It expects to launch new high-end surgical robot model in 2027. With enhanced visualisation and ergonomics, massive computing power, and greater surgeon autonomy, the new products will position the company at the forefront of the domestic players, competing directly with Intuitive Surgical’s most advanced model – da Vinci 5. The move will also allow the company to price these new products at favourable prices and promote a strategic shift towards high-end market share.
BUY (Maintained)
Current price:
Target price:
Upside:
Previous TP :
HK$27.88
HK$37.00
32.7%
HK$56.00
Analyst
Analyst
IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS
This report is provided subject to, and must be read together with, the full Disclosures / Disclaimers available at this link, which are incorporated by reference into this report. In particular, this report is intended for general circulation and informational purposes only and does not constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report. By accessing, receiving or using this report, you acknowledge that you have read, understood and agreed to be bound by the Disclosures / Disclaimers, as may be amended, supplemented or updated from time to time.
